E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
High blood pressure |
Hoge bloeddruk |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The aim of this study is to assess and compare the pharmacokinetic parameters of the newly developed amlodipine besilate oral liquid 0,5 mg/ml with commercial Norvasc 5 mg tablets. |
Het doel van dit onderzoek is om de farmacokinetische parameters van de nieuw ontwikkelde amlodipine besilaat orale drank 0,5 mg/ml en commerciele Norvasc 5 mg tabletten te bepalen en te vergelijken. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to assess the taste of the oral liquid. |
Het secundaire doel is om de smaak van de orale drank te bepalen. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subject is healthy
•Subject is Caucasian
•Age is between 18-55 years
•Body Mass Index (BMI) is between 19-25
•Written informed consent
|
•Proefpersoon is gezond
•Proefpersoon is Kaukasisch
•Leeftijd is tussen 18-55 jaar
•Body Mass Index (BMI) ligt tussen 19-25
•Toestemmingsverklaring is getekend |
|
E.4 | Principal exclusion criteria |
Sitting blood pressure lower than 120 mmHg systolic and/or 80 mmHg diastolic in resting conditions
•Use of medication, both medicines on prescription and over-the-counter medicines, excluding contraceptives
•Subject is familiar with one of the contra-indications of amlodipine: hypersensitivity to dihydropyridine derivatives, severe hypotension, shock (including cardiogenic shock), obstruction of the outflow tract of the left ventricle (e.g. aortic stenosis), hemodynamically unstable heart failure after acute myocardial infarction (16-17)
•Allergy for one of the substances of both formulations
•Pregnancy
•Smoking
•Subject has history of alcohol or drug abuse
|
•Bloeddruk lager dan 120 mmHg systolische en/of 80 mmHg diastolische bloeddruk in rust gemeten als de proefpersoon zit
•Gebruik van geneesmiddelen, zowel op recept als vrij verkrijgbare middelen, met uitzondering van anticonceptie.
•Proefpersoon is bekend met een van de contra-indicaties van amlodipine: overgevoeligheid voor dihydropyridine derivaten, ernstige hypotensie, shock (inclusief cardiale shock), verstopping van het uitgaande bloedvat van de linker ventrikel (oftewel stenose van de aorta), hemodynamisch instabiel hartfalen na een acuut myocard infarct
•Allergie voor een van de bestanddelen van een van de onderzoeksgeneesmiddelen
•Zwangerschap
•Roken
•Proefpersoon heeft een verleden met alcohol- of drugsmisbruik |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The pharmacokinetic parameters Cmax, tmax, AUC0-72, AUC∞ of amlodipine besilate oral liquid 0,5 mg/ml and Norvasc tablets 5 mg will be assessed. |
De farmacokinetische parameters Cmax, tmax, AUC0-72 en AUC∞ van amlodipine besilaat orale drank 0,5 mg/ml en Norvasc tabletten 5 mg zullen worden bepaald. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
All pharmacokinetic parameters will be evaluated after completion of the study. |
Alle farmacokinetische parameters zullen geevalueerd worden nadat het onderzoek voltooid is. |
|
E.5.2 | Secondary end point(s) |
Secondary, the taste of the amlodipine besilate oral liquid 0,5 mg/ml will to be determined using a questionnaire. |
aast de farmacokinetiek zal ook de smaak van de amlodipine besilaat orale drank 0,5 mg/ml beoordeeld worden aan de hand van een vragenlijst. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The taste of amlodipine besilate oral liquid 0,5 mg/ml will be evaluated by the subjects directly after intake using a questionnaire. The questionnaires will be evaluated by the investigators after completion of the study. |
De smaak van amlodipine besilaat orale drank 0,5 mg/ml zal door de proefpersonen direct na inname beoordeeld worden aan de hand van een vragenlijst. De vragelijsten zullen geevalueerd worden door de onderzoekers nadat het onderzoek voltooid is. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Andere formulering (amlodipine (Norvasc) tablet 5 mg) |
Other formulation (amlodipine (Norvasc) tablet 5 mg) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |